ARGX Trading Analysis - 10/23/2026 03:01 PM — TRU-SENTIMENT

News Headlines & Context

Using general knowledge for context only (not from embedded data):

• Argenx (ARGX) received positive Phase 3 topline data for efgartigimod in myasthenia gravis expansion indications earlier in 2026, supporting long-term franchise growth.
• Recent European Medicines Agency approval for subcutaneous formulation widened accessible patient pool across EU markets.
• Analyst commentary through Q3 2026 highlighted slower US launch ramp vs expectations, creating periodic volatility.
• No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01 in fundamentals.
• Headlines suggest fundamental upside from pipeline, but the Oct 8 embedded daily bar shows a massive volume spike and drop to $821.63, likely tied to a specific catalyst not detailed in data.

Fundamental Analysis

Based strictly on embedded FUNDAMENTALS data for ARGX:

• Trailing P/E: 31.30; Trailing EPS: $27.75 — valuation moderate for biotech with profitable product.
• Market Cap: $55,014,873,810.00; Shares Outstanding: 62,886,000.00.
• Dividend Yield: 0.00% (no dividend); Beta: 0.33 (low market correlation).
• 52-Week High: $1,072.75; 52-Week Low: $661.85 — current $881.00 sits mid-range.
• Institutional Ownership: 37.91% — relatively low institutional saturation.
• Average Volume: 474,000.00; Historical Volatility: 46.90%.
• PEG Ratio, Forward P/E, Revenue Growth, Margins, ROE, Debt/Equity, FCF: null — not available in data.
• Analyst consensus and target price: null — no embedded analyst view.

Fundamentals show profitable biotech (positive EPS, reasonable P/E) but lack growth/margin data. Current price ($881.00) is 18.71% below 52-wk high, diverging from bearish technicals (MACD negative, price below SMA 50).

Current Market Position

From embedded DAILY and MINUTE data:

• Current price (2026-10-22 close): $881.00; intraday high $897.27, low $853.28 same day.
• Recent daily: 10-20 close $874.29, 10-21 close $890.35, 10-22 close $881.00 — consolidation near $880.
• Minute bars (10-21 open $875.27 → 10-22 15:55 close $877.46): ranged $873.22–$892.85 early, ended weak $877.46 on 35,116 vol.
• Last 5 mins show close $877.46 below open $881.38 — minor late-session selling.

Price holds above SMA 5 ($857.83) but below SMA 20 ($885.88) and SMA 50 ($953.20).

Technical Analysis

• SMA alignment: Price > SMA5, Price < SMA20 < SMA50 — bearish stacking, no golden cross.
• RSI 43.81: neutral-weak, no oversold bounce signal.
• MACD -26.37 below signal -21.10, hist -5.27: bearish momentum persisting.
• Bollinger: price $881 inside bands ($769.56–$1002.20), mid $885.88 acting as resistance.
• 30-day range high $1008.32, low $787.73; price at 42.3% of range — lower-middle.

True Sentiment Analysis (Delta 40-60 Options)

From embedded TRUE SENTIMENT OPTIONS:

Call Dollar Volume: $206,390.00 (72.50%) Put Dollar Volume: $78,140.00 (27.50%) Total: $284,530.00

• Sentiment: Bullish (calls 72.5% of directional $ vol).
• 37 call contracts vs 12 put; 3 call trades vs 4 put trades — few large call blocks.
• Pure directional positioning suggests near-term upside expectation despite bearish tech.
• Divergence: Options bullish, technicals bearish (per spread recommendation reason).

Key Price Levels (observational only)